Peptide vs protein: what is the difference? Peptides compared with proteins, hormones, collagen and approved medicines

What is the difference between a peptide and a protein, and between a peptide and a polypeptide?

A peptide and a protein are both chains of amino acids joined by peptide bonds, and the difference is length and, in practice, convention. Peptide structure databases classify polypeptides with fewer than 50 amino acids as peptides, and a 2026 study argues that this length rule mixes together very different cases (Hamdani et al., Protein Science, 2026). In drug development, peptides generally sit between 500 and 5,000 daltons, a size between small-molecule drugs and large proteins (Wang et al., Signal Transduction and Targeted Therapy, 2022). The MeSH vocabulary lists polypeptide as an entry term under Peptides, treating the two words as one concept (MeSH record for Peptides, checked 14 October 2026).

Function often differs along the same line. Collagens are described as the most abundant high-molecular-weight proteins, with mainly a structural role (Silva et al., Marine Drugs, 2014), while peptides often act as signals: insulin, oxytocin, vasopressin and gonadotropin-releasing hormone (GnRH) are natural peptide hormones (Wang et al., 2022). The table below sets the two beside a steroid hormone.

Digestion links the two. Dietary protein is broken into short peptides, and the intestine absorbs di- and tripeptides through the PEPT1 transporter (Daniel, Annual Review of Physiology, 2004). The peptide bond page explains the link that joins every chain.

The question of whether protein is better than peptides compares things that are not rivals. A protein is a long chain and a peptide a short one, and either can be food, a hormone or a medicine. None of the sources checked compares them head to head.

How does a peptide differ from a hormone?

A peptide is defined by structure, a chain of amino acids, and a hormone by role, a chemical signal released in one place to act in another. The two sets overlap. Insulin, oxytocin, vasopressin and GnRH are peptide hormones (Wang et al., 2022). Steroid hormones such as testosterone are hormones that are not peptides, because they are built from cholesterol (Miller and Auchus, Endocrine Reviews, 2011). Many peptides, such as antimicrobial peptides and cell-penetrating peptides, are not hormones at all (Mookherjee et al., Nature Reviews Drug Discovery, 2020; Milletti, Drug Discovery Today, 2012).

Sport's anti-doping list follows the same split. WADA's 2026 Prohibited List keeps anabolic agents, including steroids, in class S1 and peptide hormones, growth factors, related substances and mimetics in class S2, and bans both classes at all times (WADA 2026 Prohibited List, in force from 1 January 2026). The page on what peptides are answers the related question of whether peptides are steroids.

What is the difference between synthetic and natural peptides?

A natural peptide is made by a living organism and a synthetic peptide is made in a laboratory or factory, and the molecule can be identical. Peptides have been produced and modified by both chemical and biological methods (Wang et al., 2022). Chemical synthesis builds the chain on a solid support one amino acid at a time, and Fmoc synthesis is now the method of choice (Behrendt et al., Journal of Peptide Science, 2016). Origin does not decide safety or legal status. The TGA treats unapproved peptide products as unassessed for safety, quality and effectiveness, whatever their origin (TGA, 23 September 2026).

Developers also change peptides on purpose. Approved peptide drugs such as liraglutide, semaglutide and insulin degludec carry fatty acids, and Wang et al. report that such modifications lengthen the time the drug stays in the circulation (Wang et al., 2022).

What are the differences between research peptides and compounded peptides?

Research peptides are laboratory reference materials labelled for research use only, while compounded peptides are prepared by a pharmacist or practitioner for a particular patient. The TGA says a research use only or not for human use label does not change whether a product is regulated as a therapeutic good (TGA guidance on peptide regulation, checked 14 October 2026). Compounded goods are generally exempt from the register of therapeutic goods only when made for a particular person or by a hospital pharmacist for the hospital's patients (TGA safety advisory, 13 April 2026).

Neither label makes a product approved. The TGA's April 2026 advisory names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products, and its page for practitioners adds that compounded peptide products may be therapeutic goods subject to manufacturing, supply, prescribing and advertising controls (TGA safety advisory, 13 April 2026; TGA, information for health practitioners, checked 14 October 2026). The law hub records schedule status by compound.

How do collagen peptides compare with marine and bovine collagen?

Collagen peptides are hydrolysed collagen, collagen broken into small pieces. Marine collagen comes from fish and other aquatic organisms, bovine collagen from cattle, and the most common industrial sources are bovine and porcine, with marine collagen an emerging alternative (Silva et al., 2014). Marine collagens are predominantly type I (Bartoletti et al., Clinical, Cosmetic and Investigational Dermatology, 2025). No head-to-head human trial of marine against bovine hydrolysate was identified in the 2025 review checked for this page, which states that high-level human studies are scarce for both and that no head-to-head comparisons exist (Bartoletti et al., 2025). A claim that one is better lacks direct trial support in that review.

Allergy is one documented difference. In a 2000 laboratory analysis of serum samples from three small patient groups (10, 2 and 15 patients), IgE antibodies showed little cross-reactivity between fish and bovine gelatins, and the study tested gelatin and not collagen supplements (Sakaguchi et al., Journal of Allergy and Clinical Immunology, 2000). The 2025 marine collagen review states that marine collagen avoids the risk of transmitting zoonotic prion disease such as bovine spongiform encephalopathy, which is the review's statement from the literature and not a trial result (Bartoletti et al., 2025).

On skin, a 2021 meta-analysis of 19 randomised, double-blind, controlled trials with 1,125 participants found results favouring hydrolysed collagen over placebo for skin hydration, elasticity and wrinkles, and a published comment raised concerns about the heterogeneity of the included studies, which limits how far the pooled result can be read (de Miranda et al., International Journal of Dermatology, 2021; Peres et al., International Journal of Dermatology, 2022).

What have studies found about peptides in skin care, and are multi-peptide serums good for skin?

In the sources checked for this page, controlled studies of topical cosmetic peptides are few and short. They include a 12-week split-face trial of 93 women aged 35 to 55, in which a moisturiser containing the palmitoyl pentapeptide pal-KTTKS gave significant improvement in wrinkles and fine lines against a control moisturiser, a single trial of one formulation in one age band that does not establish results for other peptides (Robinson et al., International Journal of Cosmetic Science, 2005). None of the sources opened tested a multi-peptide serum, a mix of several peptides, so no study result is available for that product type, and none ranked one peptide moisturiser against another.

Oral and topical routes are different experiments. The collagen meta-analysis studied oral collagen supplements (de Miranda et al., 2021), and the topical trial studied a facial moisturiser (Robinson et al., 2005). Neither compared the two, so is peptide or collagen better for skin has no head-to-head answer in these sources.

On mature skin, none of the sources opened analysed results by age beyond the 35 to 55 range of the pal-KTTKS trial.

Evidence limits

Which peptide medicines show the largest weight or blood-sugar changes in published trials?

Placebo-controlled trials give separate figures. In the 68-week STEP 1 trial in 1,961 adults without diabetes, mean body weight fell by 14.9% with semaglutide against 2.4% with placebo, in a trial funded by the maker of semaglutide that applies to that medicine and population (Wilding et al., New England Journal of Medicine, 2021). In the 72-week SURMOUNT-1 trial in 2,539 adults without diabetes, weight fell by 15.0%, 19.5% and 20.9% across the three tirzepatide groups against 3.1% with placebo, in a trial supported by the maker of tirzepatide, so it describes that medicine in that population only (Jastreboff et al., New England Journal of Medicine, 2022). In the 40-week SURPASS-2 trial in 1,879 adults with type 2 diabetes, glycated haemoglobin fell by 2.01, 2.24 and 2.30 percentage points across the three tirzepatide groups against 1.86 with semaglutide, a head-to-head result limited to those two medicines and that trial population (Frías et al., New England Journal of Medicine, 2021).

Newest depends on the date of the trial, and the most recent of these was published in 2025. Retatrutide, an investigational peptide, was in clinical trials in humans and not approved by the TGA or a comparable international regulator as of the TGA's 14 September 2026 advisory (TGA safety advisory, 14 September 2026). How retatrutide compares with Mounjaro and Ozempic reads that record. Research material is not a substitute for an approved medicine, and these results describe medicines studied under trial and regulatory conditions only.

What have studies found about peptides and joint, tendon or muscle injury?

The evidence is mostly from animals. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies, 35 of them preclinical, and found improved functional, structural and biomechanical outcomes in animal models of muscle, tendon, ligament and bone injury, which does not establish the same effects in humans (Vasireddi et al., HSS Journal, 2025). The one clinical study was a small retrospective report on chronic knee pain of unspecified cause, in which 7 of 12 patients reported relief lasting more than six months, a design that cannot show cause (Vasireddi et al., 2025). The same review found no clinical safety data (Vasireddi et al., 2025).

The review's study table lists a 1997 rat model of induced inflammatory arthritis, and the review text mentions no human arthritis study, no study of meniscus tears and no study of back pain (Vasireddi et al., 2025). The review's authors describe the evidence as level IV and level V studies and note that adverse effects are possible because of unregulated manufacturing, contamination or unknown clinical safety (Vasireddi et al., 2025). The same review records that BPC-157 lacks FDA approval and is banned in professional sports, and WADA's 2026 list names it in class S0 (WADA 2026 Prohibited List). The BPC-157 Perth guide covers supply and legal context.

Do peptides build muscle, and what does the anti-doping code say?

The sources checked include no controlled human trial showing that peptides promoted for muscle gain build muscle. The TGA says peptide products promoted for weight loss, muscle growth, anti-ageing, recovery and performance enhancement are often unapproved and have not been assessed for safety, quality or effectiveness (TGA, 23 September 2026). Sport has a clear position. WADA's 2026 Prohibited List bans growth hormone fragments such as AOD-9604, growth hormone-releasing factors such as CJC-1295 and tesamorelin, secretagogues such as ipamorelin, and thymosin-beta-4 derivatives such as TB-500 at all times (WADA 2026 Prohibited List, class S2).

Words such as jacked, ripped and shredded describe appearance goals, not outcomes measured in the trials above, and the sources checked record no trial that measured them for peptides. Creatine, a common comparison, is not a peptide: its PubChem record gives C4H9N3O2 and a molecular weight of 131.13, a single small molecule rather than a chain of amino acids (PubChem record for creatine, checked 14 October 2026). A peptide-versus-creatine contest therefore compares different kinds of substance, and none of the sources compares them.

Which peptides are linked to testosterone?

Testosterone is a steroid hormone, not a peptide, but peptides sit upstream of it. WADA's 2026 Prohibited List names chorionic gonadotrophin, luteinizing hormone, GnRH and its agonist analogues, and kisspeptin as testosterone-stimulating peptides in males, and bans them at all times (WADA 2026 Prohibited List, S2.2.1). Testosterone itself has the formula C19H28O2 and no amino-acid chain (PubChem record for testosterone, checked 14 October 2026), and steroid hormones are built from cholesterol (Miller and Auchus, 2011). The question therefore has two parts: peptides that act on the hormone-producing system, and the hormone itself.

Approved medicines work in this area from the other direction. Degarelix, a GnRH receptor blocker, was first approved in 2008 for advanced prostate cancer (Wang et al., 2022). No source checked describes a peptide for raising a healthy man's testosterone, and the TGA says unapproved peptide products promoted online have not been assessed (TGA, 23 September 2026).

How is C-peptide different from insulin and from A1c, and what is it used for?

C-peptide and A1c measure different things. C-peptide reflects the body's own insulin secretion, because it is released from beta cells in equal amounts with insulin (Leighton et al., Diabetes Therapy, 2017). A1c, the glycated haemoglobin test, tracks average blood glucose, since HbA1c concentration has a close mathematical relationship with mean glycaemia (Sacks et al., Diabetes Care, 2011). A1c is therefore not the same test as C-peptide. C-peptide is also called the proinsulin connecting peptide (Shao et al., International Journal of Molecular Sciences, 2026).

The key current clinical role of C-peptide is to assist classification and management of insulin-treated patients. Its utility is greatest 3 to 5 years after diagnosis, when substantial insulin secretion suggests type 2 or monogenic diabetes, and absent C-peptide at any time confirms an absolute insulin requirement (Jones and Hattersley, Diabetic Medicine, 2013). It also supports the diagnosis of insulinoma and the assessment of low blood sugar not caused by diabetes (Leighton et al., 2017).

Which peptide is most effective for treating diabetes has no single answer in the sources checked. Approved GLP-1 medicines, pramlintide and insulin each have regulator-approved uses, and the trial figures above show how two of them compare in one head-to-head trial.

How long do peptides stay in the body?

Peptides leave the body at very different speeds, and studies report a half-life, the time for the blood level to fall by half. A review of C-peptide testing in diabetes gives insulin a half-life of 3 to 5 minutes and C-peptide of 20 to 30 minutes (Leighton et al., 2017). In a 1995 study of eight people with type 2 diabetes, a breakdown product made up 88.5% of the rise in blood GLP-1 immunoreactivity in the sample drawn 30 minutes after native GLP-1 exposure, a small study of the natural hormone and not of any research peptide (Deacon et al., Diabetes, 1995). The US label for semaglutide records a half-life of about one week, a figure for that approved medicine and not for research material (DailyMed Ozempic label, checked 14 October 2026).

A half-life is not a clearance time. Total clearance takes longer than one half-life, and no source checked gives a total clearance time for the research peptides discussed online. For retatrutide, an investigational medicine, a phase 1 study in people reported pharmacokinetic figures, in an early-phase study that does not apply to research material (Coskun et al., Cell Metabolism, 2022), and retatrutide pharmacokinetics sets out the published figures.

Is there a peptide for ADHD or for the brain?

No peptide is listed for ADHD in the table of peptide drugs approved since 2000 in Wang et al. (2022). The approved peptides in that table that act on the nervous system are taltirelin, first approved in 2000 for spinocerebellar degeneration, and ziconotide, first approved in 2004 for severe chronic pain (Wang et al., 2022). Research compounds promoted for cognition have not been evaluated by regulators: the TGA says the claims made online for unapproved peptide products, including cognitive and athletic performance, have not been evaluated for safety, quality or effectiveness (TGA safety advisory, 13 April 2026).

ADHD treatment is a clinical question outside what these sources address. For brain research, the sources checked contain animal work only: In 2021, Sun et al. tested Dihexa, a modified peptide, in a mouse model of Alzheimer's disease, with no mouse count in the abstract, an animal study that does not establish an effect in humans (Sun et al., Brain Sciences, 2021), as described on the peptide bond page.